



**FOR IMMEDIATE RELEASE**

## **MTTI announces the capability of PSVue 794 to non-invasively image arthritis**

**West Chester, Pennsylvania, May 8, 2015**---Molecular Targeting Technologies, Inc. (MTTI) announces a study conducted by Dr. Marion M Chan, Associate Professor of Microbiology and Immunology in Temple University School of Medicine, in which MTTI's PSVue 794 is used. The article, entitled "Non-invasive *in vivo* imaging of arthritis in a collagen-induced murine model with phosphatidylserine binding near-infrared (NIR) dye", has been published in *Arthritis Research & Therapy* and highlighted in the *Nature Review of Rheumatology*.

"An *in vivo* imaging product to noninvasively assess arthritis has always been of interest," said Professor Chan. "PSVue 794 provides a cost-effective reagent for assessment of inflammation in the footpads of arthritic mice and I expect that it will facilitate preclinical screening of new arthritis drugs in animal models."

"PSVue has the potential to image cell death as a means to intervene early in diseases and rapidly determine the effectiveness of treatments," said Professor Bradley D. Smith, Emil T Hoffman Professor of Chemistry and Biochemistry, University of Notre Dame and the inventor of PSVue. "Imaging of cell death is broadly useful for treatment of numerous conditions, including cardiovascular diseases, neurology, oncology and inflammation."

Chris Pak, President and CEO of MTTI said, "We are encouraged by the successful findings of PSVue in the arthritis model. Our goal is to translate these findings into clinic and allow real-time optimization of treatment protocols for arthritis patients."

**Temple University** is one of the leading urban public comprehensive research universities in America. Its School of Medicine (TUSM) established in 1901, is one of the nation's leading medical schools and an emerging leader in basic and clinical research. It develops interdisciplinary research that builds on the strengths of the Temple University research community and actively works to commercialize new discoveries through corporate partnerships and new startup companies. Based on its level of funding from the National Institutes of Health, TUSM is the second-highest ranked medical school in Philadelphia and the third-highest in the Commonwealth of Pennsylvania. According to U.S. News & World Report, TUSM is among the top 10 most applied-to medical schools in the nation. Each year, the School of Medicine educates approximately 840 medical students and 140 graduate students.

**Molecular Targeting Technologies, Inc. (MTTI)** is a privately held biotechnology company primarily focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases. MTTI has licensed and is developing two major technology platforms to provide: (i) novel small molecule drug conjugate (SMDC) cancer therapeutic, and (ii) *in vivo* imaging agents. Please visit our website: [www.mtarget.com](http://www.mtarget.com) for more information.

Contact: Chris Pak, Email: [cpak@mtarget.com](mailto:cpak@mtarget.com); Tel: (610) 738-7938;  
Marion Chan, Email: [marion.chan@temple.edu](mailto:marion.chan@temple.edu); Tel: (215) 707-8262

<http://www.nature.com/nrrheum/journal/v11/n5/full/nrrheum.2015.39.html>

###